SCLERACORP.com
SCLERA CORPORATION began as a pre-clinical contract company that tests potential ophthalmic drugs for with its novel patents.
ABOUT
SCLERA CORPORATION uses its patented intraocular implants in the large rabbit eye to induce abnormal retinal blood vessel growth that simulates retinal diseases such as either experimental diabetic retinopathy or wet aging-related macular degeneration. Pre-clinical testing of potential ophthalmic drugs with major drug companies will lead to better outcome in people facing potential irreversible blindness. Currently SCLERA is developing biodegradable non-invasive implants for improving disorders and diseases of both the retina and the brain.
TECHNOLOGY
SCLERA CORPORATION currently is involved in the research and development of novel small molecule compounds for amelioration of both retinal (back of the eye) diseases and brain disorders & diseases.
PREVIOUS & CURRENT STUDIES
Publications from SCLERA CORPORATION demonstrate the ability of its patents in promoting neovascularization within the rabbit retina and then studying the abnormal neovascularization to define novel bioactive drugs..